Nonclassic eicosanoid

Jump to: navigation, search

WikiDoc Resources for Nonclassic eicosanoid

Articles

Most recent articles on Nonclassic eicosanoid

Most cited articles on Nonclassic eicosanoid

Review articles on Nonclassic eicosanoid

Articles on Nonclassic eicosanoid in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Nonclassic eicosanoid

Images of Nonclassic eicosanoid

Photos of Nonclassic eicosanoid

Podcasts & MP3s on Nonclassic eicosanoid

Videos on Nonclassic eicosanoid

Evidence Based Medicine

Cochrane Collaboration on Nonclassic eicosanoid

Bandolier on Nonclassic eicosanoid

TRIP on Nonclassic eicosanoid

Clinical Trials

Ongoing Trials on Nonclassic eicosanoid at Clinical Trials.gov

Trial results on Nonclassic eicosanoid

Clinical Trials on Nonclassic eicosanoid at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Nonclassic eicosanoid

NICE Guidance on Nonclassic eicosanoid

NHS PRODIGY Guidance

FDA on Nonclassic eicosanoid

CDC on Nonclassic eicosanoid

Books

Books on Nonclassic eicosanoid

News

Nonclassic eicosanoid in the news

Be alerted to news on Nonclassic eicosanoid

News trends on Nonclassic eicosanoid

Commentary

Blogs on Nonclassic eicosanoid

Definitions

Definitions of Nonclassic eicosanoid

Patient Resources / Community

Patient resources on Nonclassic eicosanoid

Discussion groups on Nonclassic eicosanoid

Patient Handouts on Nonclassic eicosanoid

Directions to Hospitals Treating Nonclassic eicosanoid

Risk calculators and risk factors for Nonclassic eicosanoid

Healthcare Provider Resources

Symptoms of Nonclassic eicosanoid

Causes & Risk Factors for Nonclassic eicosanoid

Diagnostic studies for Nonclassic eicosanoid

Treatment of Nonclassic eicosanoid

Continuing Medical Education (CME)

CME Programs on Nonclassic eicosanoid

International

Nonclassic eicosanoid en Espanol

Nonclassic eicosanoid en Francais

Business

Nonclassic eicosanoid in the Marketplace

Patents on Nonclassic eicosanoid

Experimental / Informatics

List of terms related to Nonclassic eicosanoid


Nonclassic eicosanoids are biologically active signaling molecules made by oxygenation of twenty-carbon fatty acids, other than the classic eicosanoids.

Terminology

"Eicosanoid" is the collective[1] term for oxygenated derivatives of three different 20-carbon essential fatty acidsEicosapentaenoic acid (EPA), Arachidonic acid (AA) and Dihomo-gamma-linolenic acid (DGLA).

Current usage limits the term to the leukotrienes (LT) and three types of prostanoidsprostaglandins (PG) prostacyclins (PGI), and thromboxanes (TX). However, several other classes can technically be termed eicosanoid, including the hepoxilins, resolvins, isofurans, isoprostanes, lipoxins, epi-lipoxins, epoxyeicosatrienoic acids (EETs) and endocannabinoids. LTs and prostanoids are sometimes termed 'classic eicosanoids' [2][3][4] in contrast to the 'novel', 'nonclassic' or 'eicosanoid-like' eicosanoids.[5][6][7][8]

The classic eicosanoids are autocrine and paracrine mediators, active at micromolar concentrations (or lower), produced with high stereospecificity. They are produced from EPAs (chiefly AA) from either cyclooxygenase (COX) or 5-lipoxygenase.

Broadly, the nonclassic eicosanoids are the products of 20-carbon EFAs and [9]

Also included are

See also

References

  1. Funk, Colin D. (30 November 2001). "Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology". Science. 294 (5548): 1871–1875. doi:10.1126/science.294.5548.1871. Retrieved 2007-01-08.
  2. Van Dyke TE, Serhan CN (2003). "Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases". J. Dent. Res. 82 (2): 82–90. PMID 12562878. |access-date= requires |url= (help)
  3. Serhan CN, Gotlinger K, Hong S, Arita M (2004). "Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis". Prostaglandins Other Lipid Mediat. 73 (3–4): 155–72. PMID 15290791. line feed character in |title= at position 81 (help); |access-date= requires |url= (help)
  4. Anderle P, Farmer P, Berger A, Roberts MA (2004). "Nutrigenomic approach to understanding the mechanisms by which dietary long-chain fatty acids induce gene signals and control mechanisms involved in carcinogenesis". Nutrition (Burbank, Los Angeles County, Calif.). 20 (1): 103–8. PMID 14698023. |access-date= requires |url= (help)
  5. Evans AR, Junger H, Southall MD; et al. (2000). "Isoprostanes, novel eicosanoids that produce nociception and sensitize rat sensory neurons". J. Pharmacol. Exp. Ther. 293 (3): 912–20. PMID 10869392. |access-date= requires |url= (help)
  6. O'Brien WF, Krammer J, O'Leary TD, Mastrogiannis DS (1993). "The effect of acetaminophen on prostacyclin production in pregnant women". Am. J. Obstet. Gynecol. 168 (4): 1164–9. PMID 8475962.
  7. Behrendt H, Kasche A, Ebner von Eschenbach C, Risse U, Huss-Marp J, Ring J (2001). "Secretion of proinflammatory eicosanoid-like substances precedes allergen release from pollen grains in the initiation of allergic sensitization". Int. Arch. Allergy Immunol. 124 (1–3): 121–5. PMID 11306946. |access-date= requires |url= (help)
  8. Sarau HM, Foley JJ, Schmidt DB; et al. (1999). "In vitro and in vivo pharmacological characterization of SB 201993, an eicosanoid-like LTB4 receptor antagonist with anti-inflammatory activity". Prostaglandins Leukot. Essent. Fatty Acids. 61 (1): 55–64. PMID 10477044. |access-date= requires |url= (help)
  9. Cyberlipid Center accessdate=2007-11-02. "Prostanoids and Related Products".




Linked-in.jpg